John Stagg is Professor at the Faculty of Pharmacy of University of Montreal and Lab Head at the CRCHUM since 2010. An established cancer immunologist, Dr. Stagg cumulates over 100 research publications. Dr Stagg is known for having identified the adenosine-producing enzyme CD73 as a novel target in immuno-oncology and for contributing to the development of therapeutic agents now in Phase 2 clinical trials. Dr. Stagg is also co-founder and SAB member of Surface Oncology, a clinical-stage biotech, and member of the board of directors of BioCanRx, Canada’s immunotherapy network.

The Stagg lab has also identified novel potential targets in immune-oncology to overcome resistance to anti-PD-1/CTLA-4 immune checkpoint blockade. The Stagg lab uses state-of-the-

technologies to study tumor immunity, including bulk and single-cell RNAseq, flow cytometry, metabolomics, spatial omics and deep learning.

The Stagg lab is funded by CIHR, FRQS, the Terry Fox Research Institute, the Quebec Cancer Consortium, Ovarian Cancer Canada, IVADO-Genome Quebec and the Famille Sabourin Research Chair.